Stay updated with breaking news from Trial Collaboration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 -- Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 -- GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2...
– Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million – – GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 – – Conference Call... | November 1, 2022
A study in JAMA Neurology finds that antidepressants do not reduce depression symptoms more than placebo in patients recovering from a stroke.
Antidepressants had a slight short-term effect on reducing the likelihood of depression diagnosis but there was no long-term improvement.
Form 20-F Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... | October 7, 2021